Investors

Corporate Profile

Cingulate® (CTx®) is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build and advance a pipeline of branded next-generation pharmaceutical products. These will be designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas, such as anxiety disorders, where PTR™ technology may be employed to develop future product candidates.

Computershare Welcome Letter

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

25 May 2023 Cingulate to Present at 13th Annual LD Micro Invitational

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it

12 May 2023 Cingulate, Indegene to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that

10 May 2023 Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc.

Sign-up for Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
Event
News
Weekly Summary

Contact IR

Thomas Dalton
Head of Investor & Public Relations
(913) 942-2301
IR@cingulate.com

Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.